Delays in BRAF Test Results Affect Quality of Care, Therapeutic Options in Melanoma

Source: TargetedOncology, April 2022

Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.

A retrospective cohort study identified barriers to improving BRAF testing turnaround time (TAT) in patients with melanoma at the Princess Margaret Cancer Centre in Toronto, Canada.

The identification of BRAF mutations in melanoma enables targeted therapy and improves patient outcomes. Barriers to BRAF molecular testing affect the quality of care and therapeutic options.

READ THE ORIGINAL FULL ARTICLE